Once-Daily Abrocitinib Succeeds for Atopic Dermatitis

(MedPage Today) -- Abrocitinib, a once-daily Janus kinase (JAK) 1 selective inhibitor, succeeded as a treatment for moderate-to-severe atopic dermatitis, according to the phase III JADE MONO-2 trial.
In the 12-week double-blind study of 391 individuals...